DE2364373A1 - Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide - Google Patents

Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide

Info

Publication number
DE2364373A1
DE2364373A1 DE2364373A DE2364373A DE2364373A1 DE 2364373 A1 DE2364373 A1 DE 2364373A1 DE 2364373 A DE2364373 A DE 2364373A DE 2364373 A DE2364373 A DE 2364373A DE 2364373 A1 DE2364373 A1 DE 2364373A1
Authority
DE
Germany
Prior art keywords
contg
mucopolysaccharide
estriol
contain
prepns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE2364373A
Other languages
German (de)
Inventor
Auf Nichtnennung Antrag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Carl Hahn GmbH
Original Assignee
Dr Carl Hahn GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Carl Hahn GmbH filed Critical Dr Carl Hahn GmbH
Priority to DE2364373A priority Critical patent/DE2364373A1/en
Publication of DE2364373A1 publication Critical patent/DE2364373A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Abstract

Pharmaceutical and/or cosmetic prepns contg at least 2 out of the 3 cpds (I), oestriol (II) and a mucopolysaccharide (III) are new: where R1,R2 = H, Me (at least one of the gps being Me). The combination of 2 or 3 of the cpds results in a synergistic activity on the skin and esp. on the scalp. The cpds are used with conventional carriers, diluents, solvents Suitable prepns, are e.g. for the scalp an. aq. alcoholic lotion contg. (I) and (II); for the skin water-in-oil or oil-in-water emulsions, ointments or gels contg. (II) and (III) with or without (I); for the treatment of acne and alcohol contg. gel which contains (I) and (II). The prepns can contain perfumes and/or dyes and also other active ingredients esp. cholesterin, lecithin, nucleic acids, pyrimidines, purines and/or vitamins.

Description

49 149 ' 49 149 '

Anmelder; Dr. Carl Hahn GmbH, 4 Düsseldorf Applicant; Dr. Carl Hahn GmbH, 4 Düsseldorf

Pharmazeutische und kosmetische Präparate zur äußerlichen AnwendungPharmaceutical and cosmetic preparations for external use

Die vorliegende Erfindung betrifft neue pharmazeutische und/ oder kosmetische Präparate, die als WirkstoffeThe present invention relates to new pharmaceutical and / or cosmetic preparations that act as active ingredients

a) eine Verbindung der allgemeinen Formel Ia) a compound of the general formula I.

509828/0998509828/0998

worin R^ und R2 Wasserstoff oder die Methylgruppe sind und mindestens einer der Substituenten R. und Rp die Methylgruppe ist,where R ^ and R 2 are hydrogen or the methyl group and at least one of the substituents R. and Rp is the methyl group,

b) Östriol undb) estriol and

c) ein Mucopolysaccharidc) a mucopolysaccharide

enthalten, wobei mindestens zwei der drei Verbindungen a), b) und c) anwesend sind. Bevorzugt enthalten die erfindungsgemäßen Kombinationspräparate die Verbindungen der Formel 1 in Mengen von 0,01 bis 1,2 Gew.%, die Verbindung Östriol in Mengen von 0,005 bis 0,1 Gew.%' und das Mucopolysaccharid in Mengen von 0,01 bis 5,0 Gew.96.included, with at least two of the three compounds a), b) and c) being present. The combination preparations according to the invention preferably contain the compounds of formula 1 in amounts from 0.01 to 1.2% by weight , the compound estriol in amounts from 0.005 to 0.1% by weight and the mucopolysaccharide in amounts from 0.01 to 5 % , 0 wt. 96.

Die Wirkstoffe der erfindungsgemäßen Kombinationspräparate zur äußerlichen Anwendung sind zum größten Teil bekannt. Bei den Verbindungen der allgemeinen Formel I handelt es sich um die Xanthine Coffein, Theobromin und Theophyllin. Bei dem Mucopolysaccharid handelt es sich bevorzugt um Heparin und Heparinoide, die Hyaluronsäure und Chondroitinschwefelsäure und -sulphate A und B.The active ingredients of the combination preparations according to the invention for external use are for the most part known. The compounds of general formula I are the xanthines caffeine, theobromine and theophylline. In which Mucopolysaccharide is preferably heparin and heparinoids, hyaluronic acid and chondroitin sulfuric acid and sulphates A and B.

Die neuen Kombinationspräparate gemäß der vorliegenden Erfindung zeichnen sich durch eine synergistisch-verstärkte Wirksamkeit auf die Haut und insbesondere auf die Kopfhaut aus.The new combination preparations according to the present invention are characterized by a synergistic increased effectiveness on the skin and especially on the scalp.

Bevorzugt sind solche erfindungsgemäße pharmazeutische Präpa-Such pharmaceutical preparations according to the invention are preferred

50 982 8/09 98 8ADORiGiNAL50 982 8/09 98 8 ADORiGiNAL

rate, die als Xanthin das 1,3>7-Trimethylxanthin (Coffein) und als Mucopolysaccharid Heparin enthalten.rate, the 1,3> 7-trimethylxanthine (caffeine) and contain heparin as a mucopolysaccharide.

Die erfindungsgemäßen Kombinationspräparate enthalten neben den genannten Wirkstoffen zur Herstellung äußerlich anzuwendender pharmazeutischer und/oder kosmetischer Präparate übliche Träger-, Yerdünnungs- und/oder Lösungsmittel. Die wichtigsten Formen der erfindungsgemäßen Präparate sind wässrig-alkoholische Lotionen, Wasser/Öl-Emulsionen, Öl/Wasser-Emulsionen, wasserfreie Salben sowie transparente und andere Gele. Für die Behandlung der,Kopfhaut kommen bevorzugt wässrigalkoholische, eine Verbindung der Formel I und Östriol ent- The combination preparations according to the invention contain in addition to the active ingredients mentioned for the production of externally applicable common carriers, thinners and / or solvents for pharmaceutical and / or cosmetic preparations. the are the most important forms of the preparations according to the invention aqueous-alcoholic lotions, water / oil emulsions, oil / water emulsions, anhydrous ointments, as well as transparent and other gels. For the treatment of the scalp, preference is given to aqueous-alcoholic, a compound of the formula I and estriol.

haltende Lotionen, für die Behandlung der Haut bevorzugt die genannten Emulsionen, Salben und Gele in Betracht, die Östriol in Kombination mit Mucopolysaccharid allein oder in VerbindungHolding lotions, preferably the emulsions, ointments and gels mentioned for the treatment of the skin, the estriol in combination with mucopolysaccharide alone or in conjunction

enthalten mit einem Xanthin der Formel I/ Speziell für die Akne-Behandlung werden eine Verbindung der Formel I und östriol enthaltende alkoholhaltige Gele eingesetzt.Contained with a xanthine of the formula I / Especially for acne treatment a compound of formula I and estriol-containing alcohol-containing gels are used.

Die erfindungsgemäßen Kombinationspräparate können weiterhin Duftstoffe und/oder Farbstoffe enthalten. Sie können auch weitere zusätzliche Wirkungskomponenten ergebende Wirkstoffe, insbesondere Cholesterin, Lecithin, Nukleinsäuren, Pyrimidine, Purine und/oder Vitamine enthalten.The combination preparations according to the invention can also Contain fragrances and / or dyes. You can also use other active ingredients that provide additional active components, in particular contain cholesterol, lecithin, nucleic acids, pyrimidines, purines and / or vitamins.

Die erfindungsgemäßen Präparate werden nach üblichen VerfahrenThe preparations according to the invention are made by customary methods

• ORIGINAL INSPECTED . 50 98 28/0998• ORIGINAL INSPECTED. 50 98 28/0998

hergestellt. Sie werden auf den für die Anwendung auf der Haut optimalen pH-Bereich mit für diesen Zweck geeigneten Puff er systemen wie Natriummonohydrogenphosphat/Kaliumdihydrogenphosphat (Phosphatpuffer) und/oder Natriumlactat/Kilchsäune (Lactatpuffer) eingestellt. Für Haarpräparate ist der optimale pH-Bereich 6,0 bis 7,0, für Hautpräparate 5,4 bis 5,8.manufactured. They are adjusted to the optimal pH range for application on the skin with suitable for this purpose Buffer systems such as sodium monohydrogen phosphate / potassium dihydrogen phosphate (Phosphate buffer) and / or sodium lactate / Kilchsäune (Lactate buffer). For hair preparations the optimal pH range is 6.0 to 7.0, for skin preparations 5.4 to 5.8.

Die folgenden Beispiele dienen der weiteren Erläuterung der vorliegenden Erfindung.The following examples serve to further explain the present invention.

Beispiel 1example 1

Herstellung von alkoholisch-wässrigen, Coffein und östriol enthaltenden Lotionen.Production of alcoholic-aqueous, caffeine and estriol containing lotions.

a) Zusammensetzunga) Composition GewichtsteileParts by weight CoffeinCaffeine 0,180.18 östriolestriol 0,0080.008 IsopropanolIsopropanol 3535 HexadecylalkoholHexadecyl alcohol 0,10.1 EiweißhydrolysatProtein hydrolyzate 0,10.1 KonservansConservant 0,30.3 Destilliertes WasserDistilled water ad 100ad 100 b) Zusammensetzungb) Composition GewichtsteileParts by weight CoffeinCaffeine 0,220.22 östriolestriol 0,0120.012

509828/09 98509828/09 98

Isopropanol Hexadecylalkohol Eiweißhydrolysat Konservans Destilliertes WasserIsopropanol hexadecyl alcohol protein hydrolyzate Conservant distilled water

60
0,5 5,0 0,3 ad 10060
0.5 5.0 0.3 ad 100

Die Bestandteile wurden in Isopropanol und der wesentlichen Menge des destillierten Wassers vollständig gelöst und mit destilliertem Wasser auf 100 Gew.% aufgefüllt.The ingredients were completely dissolved in isopropanol and the substantial amount of distilled water and with distilled water made up to 100% by weight.

Beispiel 2Example 2

Herstellung einer Östriol und o6-Heparin enthaltenden Wasserin-Öl-Emulsion (W/0-Emulsion).Production of a water-in-oil emulsion containing estriol and o6-heparin (W / 0 emulsion).

Zusammensetzungcomposition GewichtsteileParts by weight östriolestriol 0,0080.008 iiC-HepariniiC heparin 0,120.12 Gemisch höher-molekularer Ester,
vorwiegend Mischester aus
Pentaerythrit-Fettsäureester und
Zitronensäurealkohole sterMixture of higher molecular esters,
predominantly mixed esters
Pentaerythritol fatty acid esters and
Citric Acid Alcohols 7,07.0 Erdnußöl ■Peanut oil ■ 10,010.0 ölsäuredecylesteroleic acid decyl ester 5,05.0 Bienenwachs, weißBeeswax, white 0,80.8 Vaseline, weißVaseline, white 19,019.0 n-0ctadecanoln-octadecanol 3,03.0 oC-Tocopherol (Antioxidans)oC-tocopherol (antioxidant) 0,05 -0.05 -

509828/0998509828/0998

Phenonxp (Konservierungsmittel;Phenonxp (preservative; 0,30.3 Demineralisiertes WasserDemineralised water ad 100ad 100 Zusammensetzungcomposition GewientsteiIeGewientsteiE östriolestriol 0,0120.012 iC-HepariniC-heparin 0,180.18 Gemisch höher-molekularer Ester,
vorwiegend Mischester aus
Pentaerythrit-Fettsäureester und
ZitronensäurealkoholesterMixture of higher molecular esters,
predominantly mixed esters
Pentaerythritol fatty acid esters and
Citric acid alcohol ester 8,08.0 ErdnußölPeanut oil 20,020.0 ölsäuredecylesteroleic acid decyl ester 4,04.0 Bienenwachs, weißBeeswax, white 2,02.0 Vaseline, weißVaseline, white 9,09.0 n-Octadecanoln-octadecanol 5,05.0 cC-Tocopherol (Antioxidans)cC-tocopherol (antioxidant) 0,050.05 Phenonip (Konservierungsmittel)Phenonip (preservative) 0,30.3 Demineralisiertes WasserDemineralised water ad 100ad 100

Die Bestandteile wurden innig mit den wasserfreien ölbestandteilen vermischt und sodann das demineralisierte Wasser unter heftigem mechanischen Rühren eingemischt.The ingredients became intimate with the anhydrous oil ingredients mixed and then the demineralized water under vigorous mechanical stirring.

Beispiel 3Example 3

Herstellung einer östriol und oC-Heparin enthaltenden öl-in-Waeeer-Ejaulsion (0/¥-Emulsion).Production of an oil-in-waeeer ejaulsion containing oestriol and oC-heparin (0 / ¥ emulsion).

509828/0998509828/0998

a) Zusammensetzung ' Gewichtsteile Östriol 0,008 c£-Heparin 0,12a) Composition : parts by weight of estriol 0.008 c £ -heparin 0.12

äthoxylierter Cetylsteary!alkoholEthoxylated cetylstearyl alcohol

mit ca. 12 Molekülen Äthylenoxidwith approx. 12 molecules of ethylene oxide

pro Alkoholmolekül ' 2per alcohol molecule '2

Gemisch aus Mono- und DiglyceridenMixture of mono- and diglycerides

der Palmitin- und Stearinsäure 12of palmitic and stearic acid 12

2-Octyldodecanol 102-octyldodecanol 10

Capryl-Caprinsäuretriglycerid 15Caprylic-capric acid triglyceride 15

1,2-Propylenglykol 51,2-propylene glycol 5

Nipastat (Konservans) 0,18Nipastat (canned food) 0.18

Demineralisiertes Wasser ad 100Demineralized water ad 100

b) Zusammensetzung Gewichtsteile östriol 0,012 oC-Heparin 0,17b) Composition parts by weight of estriol 0.012 oC-heparin 0.17

äthoxylierter Cetylstearylalkoholethoxylated cetostearyl alcohol

mit ca. 12 Molekülen Äthylenoxidwith approx. 12 molecules of ethylene oxide

pro Alkoholmolekül ' 3per alcohol molecule '3

Gemisch aus Mono- und Diglyceriden .Mixture of mono- and diglycerides.

der Palmitin- und Stearinsäure 15of palmitic and stearic acid 15

2-0ctyldodecanol 202-octyldodecanol 20

Capryl-Caprinsäuretriglycerid 8Caprylic-capric acid triglyceride 8

1,2-Propylenglykol 0 r 51,2-propylene glycol 0 r 5

Nipastat (Konservans) 0,18Nipastat (canned food) 0.18

Demineralisiertes Wasser ad 100Demineralized water ad 100

Die Bestandteile wurden wie im Beispiel 2 beschrieben vermischt. The ingredients were mixed as described in Example 2.

5098 2 8/09985098 2 8/0998

Beispiel 4Example 4

Herstellung einer Östriol und oC-Heparin enthaltenden, wasserfreien Salbe.Production of an anhydrous containing estriol and oC-heparin Ointment.

a) Zusammensetzung Gewichtsteile a) Composition parts by weight

^Heparin^ Heparin 0,120.12 östriolestriol 0,010.01 GlycerinmonostearatGlycerol monostearate 12,012.0 äthoxylierter Cetylstearylalkohol
mit ca. 20 Molekülen Äthylenoxid
pro Alkoholmolekülethoxylated cetostearyl alcohol
with approx. 20 molecules of ethylene oxide
per alcohol molecule 2,52.5 Cholesterincholesterol 0,80.8 LecithinLecithin 0,80.8 «CrTocopherol (Antioxidans)«C r tocopherol (antioxidant) . 0,05. 0.05 ölsäuredecylester adoleic acid decyl ester ad 100100 Zusammensetzung GewichtsteileComposition parts by weight

cC-Heparin 0,17cC-heparin 0.17

östriol 0,015estriol 0.015

Glycerinmonostearat 16,0Glycerol monostearate 16.0

äthoxylierter Cetylstearylalkoholethoxylated cetostearyl alcohol

mit ca. 20 Molekülen Äthylenoxidwith approx. 20 molecules of ethylene oxide

pro Alkoholmolekül 3,5per alcohol molecule 3.5

Cholesterin 1,0Cholesterol 1.0

Lecithin - 1,0Lecithin - 1.0

oC-Tocopherol (Antioxidans) 0,18oC-tocopherol (antioxidant) 0.18

ölsäuredecylester ad 100oleic acid decyl ester ad 100

509828/0998509828/0998

Die Bestandteile wurden in einer Salbenmühle (Dreiwalzwerk mit Hartporzellanwalzen) innig vermischt, bis eine homogene Salbe erreicht war.The ingredients were intimately mixed in an ointment mill (three-roll mill with hard porcelain rolls) until homogeneous Ointment was reached.

Beispiel 5Example 5

Herstellung eines Coffein, Östriol und oC-Heparin enthaltenden, transparenten Gels.Production of a caffeine, estriol and oC-heparin containing, transparent gels.

a) Zusammensetzung GewichtsteiIe a) Composition by weight

östriolestriol 0,0080.008 18,018.0 0,80.8 o6-Heparino6-heparin 0,170.17 Palmitinsäureisopropylester 6,0Isopropyl palmitate 6.0 0,20.2 CoffeinCaffeine 0,40.4 LecithinLecithin ad 100ad 100 äthoxylierter Cetylstearylalkohol
mit ca. 30 Molekülen Äthylenoxid
pro Alkoholmolekül 11,0ethoxylated cetostearyl alcohol
with about 30 molecules of ethylene oxide
per alcohol molecule 11.0 Nipastat (Konservans)Nipastat (canned food) GewichtsteileParts by weight PolyblfettsäureesterPoly fatty acid esters Destilliertes WasserDistilled water 0,0100.010 b) Zusammensetzungb) Composition 0,250.25 östriolestriol 0,60.6 «^-Heparin«^ -Heparin CoffeinCaffeine

äthoxylierter Cetylstearylalkohol mit ca. 30 Molekülen Äthylenoxid . pro Alkoholmolekül . 13»0Ethoxylated cetostearyl alcohol with approx. 30 molecules of ethylene oxide . per alcohol molecule. 13 »0

509828/0998509828/0998

Polyolfettsäureester 20,0Polyol fatty acid ester 20.0

Palmitinsäureisopropylester 4,0 . Lecithin 1,1Isopropyl palmitate 4.0. Lecithin 1.1

Nipastat (Konservans) 0,2Nipastat (canned food) 0.2

Destilliertes Wasser ad 100Distilled water ad 100

Der bei ca. 900C geschmolzenen Fettphase wird ca. 2/3 der Wasserphase gleicher Temperatur zugegeben. Das entstandene Gel wird unter Rühren auf ca. 500C -abgekühlt, die Wirkstoffe in der restlichen Wassermenge gelöst oder aufgeschwemmt, •zugegeben und der Rührprozeß kurz nach der Verteilung beendet, um die Einarbeitung von Luft zu vermeiden.The molten at about 90 0 C fat phase is about 2/3 of the same temperature of the water phase was added. The resulting gel is -abgekühlt with stirring to about 50 0 C, releasing the active ingredients in the remaining amount of water or suspended, • added and the stirring process ends soon after the distribution to the incorporation to avoid air.

Beispiel 6Example 6

Herstellung eines Coffein und Östriol enthaltenden Gels für die Aknebehandlung.Manufacture of a gel containing caffeine and estriol for the acne treatment.

a) Zusammensetzung Gewichtsteile a) Composition parts by weight

östriolestriol 0,010.01 CoffeinCaffeine . 0,8. 0.8 äthoxylierter Cetylstearylalkohol
mit ca. 30 Molekülen Äthylenoxid
pro Alkoholmolekülethoxylated cetostearyl alcohol
with about 30 molecules of ethylene oxide
per alcohol molecule 11,011.0 PolyolfettsäureesterPolyol fatty acid esters 18,018.0 PalmitinsäureisopropylesterIsopropyl palmitate 6,06.0 Äthanol 70 %Ethanol 70% 0,50.5

509828/0998509828/0998

LecithinLecithin 0,80.8 20,020.0 Bronopol (Konservans)Bronopol (canned food) 0,020.02 4,0
10,04.0
10.0 Destilliertes WasserDistilled water ad 100ad 100 1,21.2 b) Zusammensetzungb) Composition GewichtsteileParts by weight 0,020.02 östriolestriol 0,070.07 ad 100ad 100 CoffeinCaffeine 1,11.1 äthoxylierter Cetylstearylalkohol
mit ca. 30 Molekülen Äthylenoxid.
pro Alkoholmolekül 13»0ethoxylated cetostearyl alcohol
with about 30 molecules of ethylene oxide.
per alcohol molecule 13 »0 PolyolfettsäureesterPolyol fatty acid esters Palmitinsäureisopropylester
Äthanol 70 % Isopropyl palmitate
Ethanol 70 % LecithinLecithin Bronopol (Konservans)Bronopol (canned food) Destilliertes WasserDistilled water

Die Herstellung des Gels geschieht entsprechend Beispiel 5.The gel is produced according to Example 5.

Bei den in den vorstehenden Beispielen aufgeführten Konser-In the case of the consoles listed in the above examples

R RR R

vierungsmitteln Nipastrat und Phenonip handelt es sich um Produkte der englischen Firma Nipa Laboratories, London/ England. Bei dem Konservierungsmittel Bronopol handelt es sich um 2-Brom-2-nitropropan-1,3-diol.It is a matter of nipastrat and phenonip as the additives to products from the English company Nipa Laboratories, London / England. The preservative bronopol is are 2-bromo-2-nitropropane-1,3-diol.

Patentansprüche:Patent claims:

509828/0998509828/0998

Claims (6)

Anmelder; Dr. Carl Hahn GmbH, 4 Düsseldorf PatentansprücheApplicant; Dr. Carl Hahn GmbH, 4 Düsseldorf patent claims 1. Pharmazeutische und/oder kosmetische Präparate zur äußeren Anwendung, enthaltend1. Pharmaceutical and / or cosmetic preparations for external use, containing a) eine Verbindung der allgemeinen Formel Ia) a compound of the general formula I. worin R1 und R2 Wasserstqffatome oder die Methylgruppe sind und mindestens einer der Substituenten R^ und R2 die Methylgruppe ist,where R 1 and R 2 are hydrogen atoms or the methyl group and at least one of the substituents R ^ and R 2 is the methyl group, b) östriol undb) estriol and c) ein Mucopolysaccharid enthalten,c) contain a mucopolysaccharide, wobei mindestens zwei der drei Verbindungen a), b) und c) anwesend sind.where at least two of the three compounds a), b) and c) are present. 2. Präparate gemäß Anspruch 1, dadurch gekennzeichnet, daß sie als Wirkstoff der Formel I das 1,3»7-Trimethylxanthin enthalten.2. Preparations according to claim 1, characterized in that they are 1,3 »7-trimethylxanthine as the active ingredient of the formula I contain. 3. Präparate gemäß Anspruch 1 oder 2, dadurch gekennzeichnet, daß das Mucopolysaccharid Heparin ist.3. Preparations according to claim 1 or 2, characterized in that the mucopolysaccharide is heparin. >5098 28/09 9 8 > 5098 28/09 9 8 23843732384373 4. Präparate gemäß Anspruch 1 bis 3» dadurch gekennzeichnet, daß sie die Verbindung der Formel I in einer Menge von
0,01 bis 1,2 Gew.% enthalten.4. Preparations according to claim 1 to 3 »characterized in that they contain the compound of formula I in an amount of
0.01 to 1.2 wt.% Contain. 5. Präparate gemäß Anspruch 1 .bis 4, dadurch gekennzeichnet, daß sie die Verbindung Östriol in einer Menge von 0,005
bis 0,1 Gevr.% enthalten.5. Preparations according to claim 1 .to 4, characterized in that they contain the compound estriol in an amount of 0.005
up to 0.1 Gevr.% included. 6. Präparate gemäß Anspruch 1 bis 5, dadurch gekennzeichnet, daß sie das Mucopolysaccharid in einer Menge von 0,01 bis 5,0 Gew,% enthalten.6. Preparations according to claim 1 to 5, characterized in that they contain the mucopolysaccharide in an amount of 0.01 to 5.0% by weight. 509828/0998509828/0998
DE2364373A 1973-12-22 1973-12-22 Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide Withdrawn DE2364373A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE2364373A DE2364373A1 (en) 1973-12-22 1973-12-22 Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2364373A DE2364373A1 (en) 1973-12-22 1973-12-22 Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide

Publications (1)

Publication Number Publication Date
DE2364373A1 true DE2364373A1 (en) 1975-07-10

Family

ID=5901843

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2364373A Withdrawn DE2364373A1 (en) 1973-12-22 1973-12-22 Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide

Country Status (1)

Country Link
DE (1) DE2364373A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2369840A1 (en) * 1976-11-08 1978-06-02 Oreal NEW COSMETIC COMPOSITION WITH SLIMMING AND ANTI-CELLULITIC ACTION
FR2437207A1 (en) * 1978-09-29 1980-04-25 Henkel Kgaa Anti dandruff hair prepn. - contg. substd. theophylline cpds. as active ingredient
EP0011821A2 (en) * 1978-11-27 1980-06-11 Henkel Kommanditgesellschaft auf Aktien Antiseborrhoeic hair treatment composition
JPS61236732A (en) * 1985-04-05 1986-10-22 フイデイ−ア・ソシエタ・ペル・アチオニ Novel local medicine
EP0305743A2 (en) * 1987-08-01 1989-03-08 Hoechst Aktiengesellschaft Pharmaceutical mixture preparation, its manufacture and use
FR2627388A1 (en) * 1988-02-18 1989-08-25 Roussel Uclaf NOVEL COSMETIC COMPOSITIONS FOR COMBATTING CELLULITE
WO1994028905A1 (en) * 1993-06-08 1994-12-22 Herbert Kuhl Oestriol-containing hormonal agent for the prophylaxis and treatment of arterial conditions in humans, method of preparing it and its use
US5442053A (en) * 1982-09-28 1995-08-15 Fidia, S.P.A. Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
US5614506A (en) * 1991-07-03 1997-03-25 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US5792753A (en) 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5811410A (en) * 1989-09-21 1998-09-22 Hyal Pharmaceutical Corporation Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6140312A (en) * 1992-02-20 2000-10-31 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
US8758819B2 (en) 2006-09-13 2014-06-24 Enhance Skin Products, Inc. Cosmetic compositions for the treatment of skin and methods thereof

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2369840A1 (en) * 1976-11-08 1978-06-02 Oreal NEW COSMETIC COMPOSITION WITH SLIMMING AND ANTI-CELLULITIC ACTION
FR2437207A1 (en) * 1978-09-29 1980-04-25 Henkel Kgaa Anti dandruff hair prepn. - contg. substd. theophylline cpds. as active ingredient
EP0011821A2 (en) * 1978-11-27 1980-06-11 Henkel Kommanditgesellschaft auf Aktien Antiseborrhoeic hair treatment composition
EP0011821A3 (en) * 1978-11-27 1981-01-14 Henkel Kommanditgesellschaft auf Aktien Antiseborrhoeic hair treatment composition
US5442053A (en) * 1982-09-28 1995-08-15 Fidia, S.P.A. Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
US5631241A (en) * 1983-10-10 1997-05-20 Fidia S.P.A. Pharmaceutical compositions containing hyaluronic acid fractions
JPS61236732A (en) * 1985-04-05 1986-10-22 フイデイ−ア・ソシエタ・ペル・アチオニ Novel local medicine
EP0305743A2 (en) * 1987-08-01 1989-03-08 Hoechst Aktiengesellschaft Pharmaceutical mixture preparation, its manufacture and use
EP0305743A3 (en) * 1987-08-01 1990-04-04 Hoechst Aktiengesellschaft Pharmaceutical mixture preparation, its manufacture and use
US5055457A (en) * 1987-08-01 1991-10-08 Hoechst Aktiengesellschaft Pharmaceutical combinations product and the preparation and use thereof
FR2627388A1 (en) * 1988-02-18 1989-08-25 Roussel Uclaf NOVEL COSMETIC COMPOSITIONS FOR COMBATTING CELLULITE
BE1005177A4 (en) * 1988-02-18 1993-05-18 Roussel Uclaf New cosmetic intended to combat cellulite.
US5985850A (en) * 1989-09-21 1999-11-16 Hyal Pharmaceuticals Corporation Compositions comprising hyaluronic acid and drugs
US6069135A (en) * 1989-09-21 2000-05-30 Hyal Pharmaceutical Corporation Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
US6194392B1 (en) 1989-09-21 2001-02-27 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US6048844A (en) * 1989-09-21 2000-04-11 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US5985851A (en) * 1989-09-21 1999-11-16 Hyal Pharmaceutical Corporation Use of hyaluronic acid or its derivatives in peritoneal dialysis and formulations thereof
US5811410A (en) * 1989-09-21 1998-09-22 Hyal Pharmaceutical Corporation Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID
US5932560A (en) * 1989-09-21 1999-08-03 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US5929048A (en) * 1989-09-21 1999-07-27 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US5830882A (en) * 1989-09-21 1998-11-03 Hyal Pharmaceutical Corporation Compositions containing a form of hyaluronic acid and a medicinal agent for treating acne in mammals and methods for administration of such composition
US5852002A (en) * 1989-09-21 1998-12-22 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US5914314A (en) * 1989-09-21 1999-06-22 Hyal Pharmaceutical Corporation Use of a form of hyaluronic acid and a medicinal agent for reducing rejection of organs transplantation in mammals
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5962433A (en) * 1990-09-18 1999-10-05 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5792753A (en) 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5614506A (en) * 1991-07-03 1997-03-25 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6140312A (en) * 1992-02-20 2000-10-31 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
WO1994028905A1 (en) * 1993-06-08 1994-12-22 Herbert Kuhl Oestriol-containing hormonal agent for the prophylaxis and treatment of arterial conditions in humans, method of preparing it and its use
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
WO2003022239A3 (en) * 2001-09-07 2003-12-24 Western Holdings Llc Stable water in oil aminophylline emulsions
US7041305B2 (en) 2001-09-07 2006-05-09 Western Holdings, Llc Stable water in oil aminophylline emulsions
US8758819B2 (en) 2006-09-13 2014-06-24 Enhance Skin Products, Inc. Cosmetic compositions for the treatment of skin and methods thereof

Similar Documents

Publication Publication Date Title
DE2364373A1 (en) Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide
DE2350315A1 (en) PHARMACEUTICAL AND COSMETIC PREPARATIONS FOR EXTERNAL USE
AT390372B (en) USE OF SOLAR FILTERS FOR STABILIZING AND IMPROVING THE SKIN COMPATIBILITY OF PREPARATIONS CONTAINING BENZOYL PEROXYDE FOR LOCAL ACNE TREATMENT
DE3206398A1 (en) S-TRIAZINE DERIVATIVES AND THEIR USE AS LIGHT PROTECTION AGENTS
DE2518430A1 (en) SKIN CONDITIONERS
EP0367939A1 (en) Storage-stable pearlescent hair-conditioning composition
EP0058887B1 (en) Antifungal compositions with a higher rate of the drug release as a stick
DE4241799C1 (en) New cosmetic agent, e.g., for treatment of hair and skin - made in two separate phases and contg. a silicone-co-poly:ol cpd.
EP0668853B1 (en) Succinic acid derivatives for use as skin conditioners
DE2704081A1 (en) MEDIUM WITH A SILICON DERIVATIVES CONTENT
DE3633453A1 (en) COMPOSITIONS BASED ON LYSINE AND ARGININE SALTS
EP0055396A1 (en) Antifungal compositions with a high release rate of the drug as an elastic liquid dressing
DE4113346A1 (en) Aq. lotion for strengthening and regeneration of hair-growth - comprises ethanol@, phospholipid(s) (derived from soya bean oil) oil, and/or grease
EP0079913B1 (en) Arene-carboxylic acid derivatives used as agents having an anti-seborrhea effect contained in cosmetic compositions
EP2174641A1 (en) Oil body mixtures containing derivatives of the isosorbid
EP0114051B1 (en) Use of sebosuppressive cosmetic products containing alkoxybenzoic esters
EP0776657A2 (en) Cosmetic and/or pharmaceutical emulsions
DE3029263A1 (en) Cosmetic cream and liq. compsn. - contg. added de-saccharified, deproteinated, opt. laevo-lactic acid-enriched sour whey serum (AT 15.12.80)
DE69131692T3 (en) METHOD AND COMPOSITION FOR IMPROVING THE UNEFFECTIVE IMPACT OF AGING
EP0191286B1 (en) Sebosuppressive cosmetic compositions containing alkoxy or alkylbenzyloxybenzoic acids or salts thereof
WO1993002660A1 (en) Emulsifier concentrates
AT352284B (en) COSMETIC PREPARATIONS FOR EXTERNAL USE
DE1035855B (en) Skin and hair care products
EP0113009A2 (en) Antimycotic compositions with a high active ingredient release in the form of gel systems
DE2654709B2 (en) Method for stabilizing valerian extract preparations

Legal Events

Date Code Title Description
8141 Disposal/no request for examination